Web8 mrt. 2024 · Since the 1990s, growing scientific progress in oncology has led to the development of new diagnostic tools and targeted therapies. Despite the increase in the incidence of many cancers, survival has significantly improved for many of these, in part because of improved treatment options including chemotherapeutic agents [].However, … WebMost patients with carboplatin HSR were not rechallenged, ... Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology …
Contact us - zenonco.io
WebHSR OncologyPRO ESMO Meeting Calendar OncologyPRO Login Search OncologyPRO Education Library Abbreviations HSR hypersensitivity reaction Legal Terms of Use … Web2 sep. 2024 · With an any-grade HSR rate of <10% and a grade 3/4 HSR rate less than 1% in cycles 3 and 4 of dose-dense paclitaxel, our study confirms the feasibility and safety of … custom stamps for mailing
Cascinu Stefano Università Vita-Salute San Raffaele
Web2024-present: Full Professor of Medical Oncology at University Vita Salute, Milano. 2015-2024: Full Professor of Medical Oncology at University di Modena e Reggio Emilia. 2010-2015: Director of Oncology Postgraduate School at Università Politecnica delle Marche. 2006 -2015: Full Professor of Medical Oncology at Università Politecnica delle ... Web20 jun. 2007 · 9097 Background: Cetuximab is a chimeric (mouse/human) IgG1 monoclonal antibody against the epidermal growth factor receptor and is approved for use in patients (pts) with colorectal cancer and head and neck squamous cell carcinoma. Hypersensitivity reactions caused by cetuximab (C-HSR) have been reported; however, the mechanism … Web1 jul. 2014 · Paclitaxel is a high-alert IV oncology medication that causes hypersensitivity reactions (HSRs) in 10%-40% of infusions, predominantly during the first or second infusion. chch solar